PCM
CERE

Prelude Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Prelude Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-270,572
Closed -$11.1M – 1600
2024
Q2 		$11.1M Buy
270,572
+145,285
+116% +$6.05M 0.77% 13
2024
Q1 		$5.3M Buy
125,287
+52,256
+72% +$2.19M 0.28% 55
2023
Q4 		$3.1M Buy
+73,031
New +$2.1M 0.21% 105

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Prelude Capital Management's CERE Position: Q3 2024 in Review

Prelude Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 270,572 shares — an estimated $11.1M sold.

Prelude Capital Management first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $11.1M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Prelude Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Prelude Capital Management sold 270,572 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $11.1M.
  • Prelude Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Prelude Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $11.1M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.